Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Comment by Possibleidiot01on Nov 25, 2023 4:14pm
121 Views
Post# 35753001

RE:OPSENS ANNOUNCES FOURTH QUARTER RESULTS

RE:OPSENS ANNOUNCES FOURTH QUARTER RESULTSResults were great ; not happy with the deal .
Cash and cash equivalents of $17.5 million at November 30, 2022 ($23.8 million at August 31, 2022).
Cash and cash equivalents of $20.5 million at May 31, 2023 ($21.9 million at 28 February, 2023).
Cash now at $18.1 million so they could have waited and got more in my opinion. Cash burn $3.8 million since February in the rampup.
Liabilities up $2 million - mostly lease related.

<< Previous
Bullboard Posts
Next >>